F-18 choline PET/CT outpaces whole-body MRI in recurrent prostate cancer

Sunday, November 28 | 12:05 p.m.-12:15 p.m. | SSA18-09 | Room S505AB
Preliminary results of an Italian study show that while whole-body MRI did not match accuracy levels of F-18 choline PET/CT in detecting the local recurrence of prostate cancer, whole-body MRI is still a promising tool in restaging patients with the disease.

In the study from the University of Rome "Tor Vergata," 12 patients with clinical characteristics of recurrent tumor underwent 3-tesla whole-body MRI and F-18 choline PET/CT. Apparent diffusion coefficient (ADC) values for the MR images and standardized uptake values (SUVs) for the PET/CT scans were calculated for all lymph nodes and bone metastases.

The analysis included a total of 40 lesions that were considered malignant, with 10 local recurrences, 25 lymph nodes, three bone lesions, and two lung metastases.

Overall sensitivity of F-18 choline PET/CT was 94%, while specificity was 76% and accuracy was 93%. For whole-body MRI, sensitivity was 78%, specificity was 94%, and accuracy was 81%.

The researchers also found a highly significant difference for the mean ADCs and SUVs for benign and malignant retroperitoneal and pelvic lymph nodes. SUVs and ADCs of bone also showed significantly higher values in bone metastases compared to normal bone.

Study co-author Guglielmo Manenti, MD, PhD, from the department of diagnostic and molecular imaging, interventional radiology, and radiotherapy, is scheduled to present the study results at RSNA 2010 in Chicago.

Page 1 of 435
Next Page